VIR Key Statistics
High
9.09
Open
8.82
Volume
1.68M
Low
8.77
Prev. Close
8.69
Trading Value
14.99M
52-Week High
11.66
Relative Volume
1.022
Amplitude (%)
3.62%
52-Week Low
4.16
Turnover Rate
1.00%
Market Cap
1.46B
P/E Ratio (TTM)
--
P/E Ratio (Annual)
2.234
P/B Ratio
1.8
P/S Ratio
22.38
Earnings Per Share (EPS)
-3.137
Dividend (TTM)
0
Dividend Yield
0.00%
Shares Outstanding
168.65M
Currency Unit
USD
VIR Price Performance
7 day
30 day
90 day
180 day
Year to date
1 Year
VIR Money Flow Distribution
VIR Daily Short Sale Volume
VIR Short Interest History
VIR Stock Snapshot
As of 2026-07-28, the Vir Biotechnology, Inc. (VIR) stock price today is 8.8. Based on this price, the company has a market capitalization of $1.46B, with a P/E ratio of --.
On 2026-07-28, VIR traded between 8.77 and 9.09. Today’s stock price is 0.34% above the daily low and 3.19% below the daily high, placing VIR near the lower end of its most recent trading range.
Trading volume currently stands at 1.68M, compared with an average daily volume of 1.65M. This suggests that trading activity is roughly in line with its usual level than usual.
Over the past year, Vir Biotechnology, Inc. shares have traded between 4.16 and 11.66. At today’s price, VIR is 111.54% above its 52-week low and 24.53% below its 52-week high.
VIR Related News
About VIR
Company Name
Vir Biotechnology, Inc.
Sector
Health Technology
Industry
Biotechnology
Exchanges
Nasdaq
Number of Employees
367
Lot Size
100
Official Website
Currency Unit
USD
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Related Stocks
VIR FAQ
© 2026 CoinGlass, all rights reserved
